Skip to main content
Premium Trial:

Request an Annual Quote

Remember When It Was the Biotechs That Got Acquired?

This article from the Wall Street Journal reports on Celgene's acquisition of Pharmion, which makes treatments for patients with blood cancer. Celgene, a biotech company, will make the purchase for $2.9 billion in cash and stock in an effort "to become a major global player in developing and marketing blood-cancer drugs," according to the article.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.